Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380:1840 - 50; http://dx.doi.org/10.1016/S0140-6736(12)60919-2; PMID: 23079588
   PubMed Web of Science ®Google Scholar
• Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R, Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513 - 7; http://dx.doi.org/10.1093/jnci/djn044; PMID: 18364507
   PubMed Web of Science ®Google Scholar
• Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831 - 6; http://dx.doi.org/10.1016/S0140-6736(00)04956-4; PMID: 11410191
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12 - 9; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; PMID: 10451482
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009; 20:1705 - 13; http://dx.doi.org/10.1007/s10552-009-9422-z; PMID: 19705288
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518 - 27; http://dx.doi.org/10.1056/NEJMoa021641; PMID: 12571259
   PubMed Web of Science ®Google Scholar
• Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 2002; 100:327 - 31; http://dx.doi.org/10.1002/ijc.10506; PMID: 12115548
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915 - 27; http://dx.doi.org/10.1056/NEJMoa061741; PMID: 17494925
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928 - 43; http://dx.doi.org/10.1056/NEJMoa061760; PMID: 17494926
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al, HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161 - 70; http://dx.doi.org/10.1016/S0140-6736(07)60946-5; PMID: 17602732
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30:Suppl 5 F123 - 38; http://dx.doi.org/10.1016/j.vaccine.2012.04.108; PMID: 23199956
   PubMed Web of Science ®Google Scholar
• Wei M-X, Li SW, Huang B, Shen WT, Su YZ, Zhang CH, Gu Y, Du HL, Zhang J, Xia NS. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity]. [in Chinese] Bing Du Xue Bao 2009; 25:245 - 50; PMID: 19769155
   PubMedGoogle Scholar
• Xie M-H, Li S-W, Shen W-T, Li Z-Y, Zhuang Y-D, Mo X-B, Gu Y, Wu T, Zhang J, Xia N. [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli]. [in Chinese] Sheng Wu Gong Cheng Xue Bao 2009; 25:1082 - 7; PMID: 19835152
   PubMedGoogle Scholar
• Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895 - 902; http://dx.doi.org/10.1016/S0140-6736(10)61030-6; PMID: 20728932
   PubMed Web of Science ®Google Scholar
• CFDA. Adverse reaction grading standards guideline for prophylactic vaccine clinical trial. 2005 Available from: http://www.sda.gov.cn/WS01/CL1616/83435.html.
   Google Scholar
• Corp. MSD. GARDASIL Prescribing Information.2013 Available from: http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf
   Google Scholar
• GlaxoSmithKline. CERVARIX Prescribing Information. 2012 Available from: http://us.gsk.com/products/assets/us_cervarix.pdf
   Google Scholar
• Miller NB. Clinical Review of Biologics License Application for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine (S. cerevisiae) (STN 125126 GARDASIL), manufactured by Merck, Inc. 2006 Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111287.pdf
   Google Scholar
• Nancy B. Miller, Roberts J. Clinical Review of Biologics License Application for Human Papillomavirus 16, 18 L1 Virus Like Particle Vaccine, AS04 Adjuvant-Adsorbed (Cervarix). 2009[http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm237976.pdf].
   Google Scholar
• Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013; In press http://dx.doi.org/10.1016/j.tibtech.2013.09.002; PMID: 24125746
   PubMed Web of Science ®Google Scholar
• Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991; 60:1445 - 56; http://dx.doi.org/10.1016/S0006-3495(91)82181-6; PMID: 1663794
   PubMed Web of Science ®Google Scholar
• Zhao Q, Modis Y, High K, Towne V, Meng Y, Wang Y, Alexandroff J, Brown M, Carragher B, Potter CS, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J 2012; 9:52; http://dx.doi.org/10.1186/1743-422X-9-52; PMID: 22356831
   PubMed Web of Science ®Google Scholar
• Salunke DM, Caspar DL, Garcea RL. Self-assembly of purified polyomavirus capsid protein VP1. Cell 1986; 46:895 - 904; http://dx.doi.org/10.1016/0092-8674(86)90071-1; PMID: 3019556
   PubMed Web of Science ®Google Scholar
• Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009; 8:17; http://dx.doi.org/10.1186/1475-2859-8-17; PMID: 19317892
   PubMed Web of Science ®Google Scholar
• Zhang J, Shih JW, Wu T, Li SW, Xia NS. Development of the hepatitis E vaccine: from bench to field. Semin Liver Dis 2013; 33:79 - 88; http://dx.doi.org/10.1055/s-0033-1338116; PMID: 23564392
   PubMed Web of Science ®Google Scholar
• Park SB. Hepatitis E vaccine debuts. Nature 2012; 491:21 - 2; http://dx.doi.org/10.1038/491021a; PMID: 23128204
   PubMed Web of Science ®Google Scholar